INSYS Therapeutics Receives FDA Fast Track Designation for Epinephrine Nasal Spray
INSYS Therapeutics, Inc. (INSY) announced on August 30 that the company received a Fast Track from the FDA for the company’s epinephrine nasal spray. The spray is an investigational drug for the treatment of anaphylaxis, a life-threatening allergic reaction requiring urgent treatment. INSYS is a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids and spray technology.
Sonal received the news and sent out an alert to subscribers at 6:00 am. The next trade took place at 6:07 am for $8.28. Regular market trading opened for the day at $8.32. INSYS Therapeutics closed at $10.67 for an event-day gain of 29%.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!